SEC Form 4 · accession 0001203311-18-000014
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clay B Siegall
Officer — President and CEO · Director
Period of report
Mar 9, 2018
Accepted (ET)
Mar 13, 2018 · 8:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 9, 2018 | M | 4,764 | $11.09 | A | 691,910 | D | |
| Common StockF3,F1 | Mar 9, 2018 | S | 4,764 | $57.76 | D | 687,146 | D | |
| Common StockF1 | Mar 9, 2018 | M | 14,068 | $11.09 | A | 701,214 | D | |
| Common StockF4,F1 | Mar 9, 2018 | S | 14,068 | $57.17 | D | 687,146 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F5 | $11.09 | Mar 9, 2018 | M | 4,764 | D | — | Aug 27, 2018 | Common Stock | 4,764 | 108,227 | D |
| Non-Qualified Stock Option (right to buy)F5 | $11.09 | Mar 9, 2018 | M | 14,068 | D | — | Aug 27, 2018 | Common Stock | 14,068 | 94,159 | D |
Explanation of responses
- F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F3Reflects sales of common stock executed in multiple transactions at prices ranging from $57.57 to $57.98. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of common stock executed in multiple transactions at prices ranging from $56.57 to $57.55. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Shares vested at a rate of 25% on 8/27/09 and monthly thereafter until all the shares were fully vested on 8/27/12.